Study of Varenicline Nasal Spray for Improving Eye Surface Health and Tear Stability in Adults with Dry Eye and Meibomian Gland Dysfunction

What this Trial Is About

This research aims to study the effects of a nasal spray treatment on the function of Meibomian glands and the health of the eye surface in people with dry eye symptoms caused by mild to moderate Meibomian gland dysfunction MGD. Dry eye disease happens when the eyes do not produce enough tears or the tears evaporate quickly, leading to discomfort such as dryness, burning, irritation, and blurred vision. The nasal spray being studied is already FDA approved for treating signs and symptoms of dry eye disease. Participants in the study will use a nasal spray containing varenicline at a dose of 0.03 mg per spray. They will self-administer one spray in each nostril twice daily, about 12 hours apart, for a total of three months. This treatment period is the main phase of the study during which the effects of the nasal spray on the eye surface and tear film will be evaluated. During the study, participants will undergo assessments at the start, one month, and three months to measure changes in tear lipid layer thickness, tear thinning rate, Meibomian gland function, tear production rate, tear breakup time, and ocular comfort. These evaluations include eye exams and questionnaires to monitor the impact of the treatment on dry eye symptoms and eye health. The study will continue until the end date in December 2026, with ongoing safety and effectiveness monitoring throughout the treatment period.

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment